A hnRNPA2B1 agonist effectively inhibits HBV and SARS-CoV-2 omicron in vivo
Protein & Cell
; (12): 37-50, 2023.
Article
en En
| WPRIM
| ID: wpr-971609
Biblioteca responsable:
WPRO
ABSTRACT
The twenty-first century has already recorded more than ten major epidemics or pandemics of viral disease, including the devastating COVID-19. Novel effective antivirals with broad-spectrum coverage are urgently needed. Herein, we reported a novel broad-spectrum antiviral compound PAC5. Oral administration of PAC5 eliminated HBV cccDNA and reduced the large antigen load in distinct mouse models of HBV infection. Strikingly, oral administration of PAC5 in a hamster model of SARS-CoV-2 omicron (BA.1) infection significantly decreases viral loads and attenuates lung inflammation. Mechanistically, PAC5 binds to a pocket near Asp49 in the RNA recognition motif of hnRNPA2B1. PAC5-bound hnRNPA2B1 is extensively activated and translocated to the cytoplasm where it initiates the TBK1-IRF3 pathway, leading to the production of type I IFNs with antiviral activity. Our results indicate that PAC5 is a novel small-molecule agonist of hnRNPA2B1, which may have a role in dealing with emerging infectious diseases now and in the future.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Antivirales
/
Interferón Tipo I
/
Virus de la Hepatitis B
/
Ribonucleoproteína Heterogénea-Nuclear Grupo A-B
/
SARS-CoV-2
/
COVID-19
Límite:
Animals
Idioma:
En
Revista:
Protein & Cell
Año:
2023
Tipo del documento:
Article